Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors

Pan Pan, Kiyoko Oshima, Yi Wen Huang, Kimberle A. Agle, William R. Drobyski, Xiao Chen, Jianying Zhang, Martha M. Yearsley, Jianhua Yu, Li Shu Wang

Research output: Contribution to journalArticle

Abstract

Free fatty acid receptor 2 (FFAR2, also named GPR43), is activated by short-chain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. FFAR2 has been suggested to regulate colonic inflammation, which is a major risk factor for the development of colon cancer and is also linked to epigenetic dysregulation in colon carcinogenesis. The current study assessed whether FFAR2, acting as an epigenetic regulator, protects against colon carcinogenesis. To mimic the mild inflammation that promotes human colon cancer, we treated mice with dextran sodium sulfate (DSS) overnight, which avoids excessive inflammation but induces mild inflammation that promotes colon carcinogenesis in the ApcMin/+ and the azoxymethane (AOM)-treated mice. Our results showed that FFAR2 deficiency promotes the development of colon adenoma in the ApcMin/+/DSS mice and the progression of adenoma to adenocarcinoma in the AOM/DSS mice. FFAR2's downstream cAMP-PKA-CREB pathway was enhanced, leading to overexpression of histone deacetylases (HDACs) in the FFAR2-deficient mice. ChIP-qPCR analysis revealed differential binding of H3K27me3 and H3K4me3 histone marks onto the promoter regions of inflammation suppressors (e.g., sfrp1, dkk3, socs1), resulting in decreased expression of these genes in the FFAR2-deficient mice. Also, more neutrophils infiltrated into tumors and colon lamina propria of the FFAR2-deficient mice. Depletion of neutrophils blocked the progression of colon tumors. In addition, FFAR2 is required for butyrate to suppress HDAC expression and hypermethylation of inflammation suppressors. Therefore, our results suggest that FFAR2 is an epigenetic tumor suppressor that acts at multiple stages of colon carcinogenesis.

Original languageEnglish (US)
JournalInternational Journal of Cancer
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Epigenomics
Colonic Neoplasms
Colon
Inflammation
Dextran Sulfate
Carcinogenesis
Azoxymethane
Histone Deacetylases
Butyrates
Adenoma
Neutrophils
Histone Code
Neoplasms
Volatile Fatty Acids
Dietary Fiber
Nonesterified Fatty Acids
Genetic Promoter Regions
Mucous Membrane
Adenocarcinoma
Bacteria

Keywords

  • Butyrate
  • Colon cancer
  • Epigenetics
  • FFAR2
  • HDAC

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. / Pan, Pan; Oshima, Kiyoko; Huang, Yi Wen; Agle, Kimberle A.; Drobyski, William R.; Chen, Xiao; Zhang, Jianying; Yearsley, Martha M.; Yu, Jianhua; Wang, Li Shu.

In: International Journal of Cancer, 01.01.2018.

Research output: Contribution to journalArticle

Pan, Pan ; Oshima, Kiyoko ; Huang, Yi Wen ; Agle, Kimberle A. ; Drobyski, William R. ; Chen, Xiao ; Zhang, Jianying ; Yearsley, Martha M. ; Yu, Jianhua ; Wang, Li Shu. / Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors. In: International Journal of Cancer. 2018.
@article{8fd1f6b57d4a4533a73d852ed14ce2d3,
title = "Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors",
abstract = "Free fatty acid receptor 2 (FFAR2, also named GPR43), is activated by short-chain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. FFAR2 has been suggested to regulate colonic inflammation, which is a major risk factor for the development of colon cancer and is also linked to epigenetic dysregulation in colon carcinogenesis. The current study assessed whether FFAR2, acting as an epigenetic regulator, protects against colon carcinogenesis. To mimic the mild inflammation that promotes human colon cancer, we treated mice with dextran sodium sulfate (DSS) overnight, which avoids excessive inflammation but induces mild inflammation that promotes colon carcinogenesis in the ApcMin/+ and the azoxymethane (AOM)-treated mice. Our results showed that FFAR2 deficiency promotes the development of colon adenoma in the ApcMin/+/DSS mice and the progression of adenoma to adenocarcinoma in the AOM/DSS mice. FFAR2's downstream cAMP-PKA-CREB pathway was enhanced, leading to overexpression of histone deacetylases (HDACs) in the FFAR2-deficient mice. ChIP-qPCR analysis revealed differential binding of H3K27me3 and H3K4me3 histone marks onto the promoter regions of inflammation suppressors (e.g., sfrp1, dkk3, socs1), resulting in decreased expression of these genes in the FFAR2-deficient mice. Also, more neutrophils infiltrated into tumors and colon lamina propria of the FFAR2-deficient mice. Depletion of neutrophils blocked the progression of colon tumors. In addition, FFAR2 is required for butyrate to suppress HDAC expression and hypermethylation of inflammation suppressors. Therefore, our results suggest that FFAR2 is an epigenetic tumor suppressor that acts at multiple stages of colon carcinogenesis.",
keywords = "Butyrate, Colon cancer, Epigenetics, FFAR2, HDAC",
author = "Pan Pan and Kiyoko Oshima and Huang, {Yi Wen} and Agle, {Kimberle A.} and Drobyski, {William R.} and Xiao Chen and Jianying Zhang and Yearsley, {Martha M.} and Jianhua Yu and Wang, {Li Shu}",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/ijc.31366",
language = "English (US)",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Loss of FFAR2 promotes colon cancer by epigenetic dysregulation of inflammation suppressors

AU - Pan, Pan

AU - Oshima, Kiyoko

AU - Huang, Yi Wen

AU - Agle, Kimberle A.

AU - Drobyski, William R.

AU - Chen, Xiao

AU - Zhang, Jianying

AU - Yearsley, Martha M.

AU - Yu, Jianhua

AU - Wang, Li Shu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Free fatty acid receptor 2 (FFAR2, also named GPR43), is activated by short-chain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. FFAR2 has been suggested to regulate colonic inflammation, which is a major risk factor for the development of colon cancer and is also linked to epigenetic dysregulation in colon carcinogenesis. The current study assessed whether FFAR2, acting as an epigenetic regulator, protects against colon carcinogenesis. To mimic the mild inflammation that promotes human colon cancer, we treated mice with dextran sodium sulfate (DSS) overnight, which avoids excessive inflammation but induces mild inflammation that promotes colon carcinogenesis in the ApcMin/+ and the azoxymethane (AOM)-treated mice. Our results showed that FFAR2 deficiency promotes the development of colon adenoma in the ApcMin/+/DSS mice and the progression of adenoma to adenocarcinoma in the AOM/DSS mice. FFAR2's downstream cAMP-PKA-CREB pathway was enhanced, leading to overexpression of histone deacetylases (HDACs) in the FFAR2-deficient mice. ChIP-qPCR analysis revealed differential binding of H3K27me3 and H3K4me3 histone marks onto the promoter regions of inflammation suppressors (e.g., sfrp1, dkk3, socs1), resulting in decreased expression of these genes in the FFAR2-deficient mice. Also, more neutrophils infiltrated into tumors and colon lamina propria of the FFAR2-deficient mice. Depletion of neutrophils blocked the progression of colon tumors. In addition, FFAR2 is required for butyrate to suppress HDAC expression and hypermethylation of inflammation suppressors. Therefore, our results suggest that FFAR2 is an epigenetic tumor suppressor that acts at multiple stages of colon carcinogenesis.

AB - Free fatty acid receptor 2 (FFAR2, also named GPR43), is activated by short-chain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. FFAR2 has been suggested to regulate colonic inflammation, which is a major risk factor for the development of colon cancer and is also linked to epigenetic dysregulation in colon carcinogenesis. The current study assessed whether FFAR2, acting as an epigenetic regulator, protects against colon carcinogenesis. To mimic the mild inflammation that promotes human colon cancer, we treated mice with dextran sodium sulfate (DSS) overnight, which avoids excessive inflammation but induces mild inflammation that promotes colon carcinogenesis in the ApcMin/+ and the azoxymethane (AOM)-treated mice. Our results showed that FFAR2 deficiency promotes the development of colon adenoma in the ApcMin/+/DSS mice and the progression of adenoma to adenocarcinoma in the AOM/DSS mice. FFAR2's downstream cAMP-PKA-CREB pathway was enhanced, leading to overexpression of histone deacetylases (HDACs) in the FFAR2-deficient mice. ChIP-qPCR analysis revealed differential binding of H3K27me3 and H3K4me3 histone marks onto the promoter regions of inflammation suppressors (e.g., sfrp1, dkk3, socs1), resulting in decreased expression of these genes in the FFAR2-deficient mice. Also, more neutrophils infiltrated into tumors and colon lamina propria of the FFAR2-deficient mice. Depletion of neutrophils blocked the progression of colon tumors. In addition, FFAR2 is required for butyrate to suppress HDAC expression and hypermethylation of inflammation suppressors. Therefore, our results suggest that FFAR2 is an epigenetic tumor suppressor that acts at multiple stages of colon carcinogenesis.

KW - Butyrate

KW - Colon cancer

KW - Epigenetics

KW - FFAR2

KW - HDAC

UR - http://www.scopus.com/inward/record.url?scp=85044521158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85044521158&partnerID=8YFLogxK

U2 - 10.1002/ijc.31366

DO - 10.1002/ijc.31366

M3 - Article

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

ER -